ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent publications have shown that Hh pathway activation is closely associated with the expansion of leukemia stem cells (LSCs) (Zhao et al., 2009), and targeting Hh pathway could overcome IM resistance in BCR–ABL positive CML (Zeng et al., 2015).